Other languages Rakovina Therapeutics Inc.

Equities

RKV

CA75103L1013

Delayed Toronto S.E. Other stock markets 03:59:51 2024-07-11 pm EDT			5-day change	1st Jan Change
0.1 ^CAD	0.00%		0.00%	+17.65%

May. 31	Rakovina Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
May. 23	Rakovina Therapeutics Inc. announced that it expects to receive CAD 1.5 million in funding	CI

Other languages

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Rakovina Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 30
Rakovina Therapeutics Announces Extensions and Expansions of Strategic Collaborations to Support AI Research	May. 08
Rakovina Therapeutics Presents At American Association Of Cancer Research Annual Meeting	Apr. 09
Rakovina Therapeutics Announces Appointment to Scientific Advisory Board	Nov. 27
Rakovina Therapeutics Appoints Prof. Artem Cherkasov to the Scientific Advisory Board	Nov. 27
Rakovina Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 26
Rakovina Therapeutics Inc. Announces Appointment of Prof. Petra Hamerlik as New Scientific Advisory Board Member	Nov. 20
Rakovina Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-28
Rakovina Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-29
Rakovina Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-27
Rakovina Therapeutics Inc. Announces Presentation of New KT-3000 Series Data At AACR Annual Meeting	23-04-20
Rakovina Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-15
Rakovina Therapeutics Second-Quarter Loss Narrows on Lower Spending	22-08-11
Rakovina Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-09
Rakovina Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-24
Rakovina Therapeutics Presents Preclinical Data on its Novel kt-3000 Series at the 2022 AACR Special Conference on Sarcomas	22-05-11
Rakovina Therapeutics Reports Q4 Net Loss of $751K	22-04-27
Rakovina Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	22-04-25
Rakovina Therapeutics Presents Preclinical Data For kt-4000 Series Compounds at AACR Annual Meeting	22-04-12
Rakovina Therapeutics Presents Evaluation of A Novel Class of Bifunctional DNA Alkylating PARP Inhibitors	22-04-12

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Rakovina Therapeutics Inc.

Equities

RKV

CA75103L1013

Other languages

Filters